skip to main content

House Passes FDA Reauthorization Act

On July 12, the House passed, by voice vote, H.R. 2430, the FDA Reauthorization Act of 2017. The Energy and Commerce Committee approved the legislation on June 7 (see The Source, 6/9/17).

The bill, sponsored by Rep. Greg Walden (R-OR), would expand user fees for prescription drugs, medical devices, generic drugs, and biosimilar products. The measure also would direct the secretary of Health and Human Services to hold a public meeting to discuss, among other topics, “the impact of exclusion criteria on the enrollment in clinical trials of particular populations, including infants and children, and pregnant and lactating women.”

The Spring 2023 internship applications are now open!Apply Now!